Shots:

• The P-III SEQUOIA study involves assessing of Pegilodecakin + Folfox (folinic acid- 5-FU- oxaliplatin) vs Folfox as monothx. in 567 patients with metastatic adenocarcinoma of the pancreas with diseases progression on one prior gemcitabine-containing regimen
• The P-III SEQUOIA study did not meet its 1EPs of overall survival. Lilly gained Pegilodecakin following the acquisition of ARMO BioSciences in Jun’2018
• Pegilodecakin is a pegylated IL-10- stimulating the body's natural defenses against cancer and expands tumor-attacking T cells and has shown clinical activity as monothx. or in combination with CT & with checkpoint inhibitor across multiple cancer indications in P-I/Ib IVY study

Click here to­ read full press release/ article | Ref: Eli Lilly | Image:FinChannel